Saturday 17 October 2026
Export ALKS’s income statement to Excel — free account
Alkermes plc
ALKS Healthcare Drug Manufacturers Specialty & Generic
Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024. In the quarter to June 2026, revenue grew 27.0%, EPS fell 99.4% and free cash flow grew 1.13%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
41.22
1.12
+2.79%
Follow ALKS
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.31 | 12.90 | 19.03 |
Piotroski F-Score |
5 | 5 | 7 | 5 | 5 | 5 | 4 | 8 | 7 | 7 |
P/S ratio |
11.40 | 9.38 | 4.18 | 2.74 | 3.05 | 3.19 | 3.81 | 2.86 | 3.05 | 3.12 |
Altman Z-Score |
9.44 | 8.24 | 4.14 | 2.31 | 1.84 | 2.49 | 2.52 | 4.04 | 6.16 | 5.33 |
P/FCF ratio |
0.00 | 0.00 | 150.78 | 0.00 | 76.77 | 50.60 | 0.00 | 13.45 | 11.71 | 9.57 |
Altman Z″-Score (non-manufacturers) |
2.05 | 1.57 | 1.71 | 0.51 | 0.65 | 1.04 | 0.46 | 3.57 | 5.46 | 6.24 |
Beneish M-Score |
(2.77) | (2.77) | (3.01) | (3.31) | (2.87) | (2.32) | (2.73) | (2.10) | (2.19) | (3.29) |
P/Operating CF |
1,124.40 | 235.92 | 75.64 | 76.16 | 47.04 | 120.68 | 4,045.85 | 44.36 | 24.98 | 27.10 |
P/B ratio |
7.03 | 7.04 | 3.91 | 2.95 | 2.97 | 3.36 | 4.06 | 3.96 | 3.25 | 2.53 |
Price to Tangible BV |
10.64 | 9.92 | 5.16 | 3.81 | 3.67 | 3.96 | 4.59 | 4.26 | 3.44 | 2.66 |
EV/Sales |
11.11 | 9.21 | 3.95 | 2.52 | 2.70 | 2.98 | 3.53 | 2.57 | 2.76 | 2.42 |
EV/EBITDA |
0.00 | 0.00 | 952.62 | 0.00 | 0.00 | 19.86 | 54.63 | 8.74 | 9.56 | 12.73 |
EV/Operating CF |
(129.85) | 433.53 | 43.49 | 40.87 | 33.90 | 34.44 | 186.31 | 10.65 | 9.78 | 6.87 |
EV/FCF |
(77.24) | (260.41) | 142.22 | (163.99) | 68.05 | 47.35 | (227.81) | 12.09 | 10.57 | 7.43 |
Quick Ratio |
3.25 | 2.29 | 2.45 | 2.03 | 2.08 | 1.80 | 1.80 | 2.13 | 2.44 | 3.04 |
Current Ratio |
3.73 | 2.78 | 2.89 | 2.46 | 2.54 | 2.25 | 2.27 | 2.86 | 3.04 | 3.55 |
Net Debt/EBITDA |
1.87 | 3.08 | (57.37) | 2.71 | 11.78 | (1.36) | (4.39) | (0.99) | (1.67) | (4.69) |
Debt/Assets |
16.43% | 15.66% | 15.30% | 15.35% | 14.10% | 14.61% | 14.93% | 13.61% | 0.00% | 0.00% |
Debt/Equity |
0.23 | 0.23 | 0.24 | 0.26 | 0.26 | 0.27 | 0.28 | 0.24 | 0.00 | 0.00 |
Asset Turnover |
0.42 | 0.51 | 0.60 | 0.65 | 0.55 | 0.59 | 0.56 | 0.81 | 0.74 | 0.65 |
Operating CF/Net income |
0.31 | (0.12) | (0.71) | (0.37) | (0.75) | (2.11) | (0.13) | 1.13 | 1.20 | 2.15 |
Capex/Depreciation |
(0.46) | (0.52) | (0.66) | (1.12) | (0.51) | (0.37) | (0.49) | (0.64) | (1.16) | (1.45) |
Interest Coverage |
(14.01) | (12.32) | (6.42) | (12.90) | (12.98) | 8.71 | (0.47) | 17.98 | 18.63 | 20.69 |
| (16.52%) | (13.10%) | (11.74%) | (17.43%) | (10.30%) | (4.42%) | (14.68%) | 31.67% | 27.52% | 14.72% | |
| (11.64%) | (8.96%) | (7.69%) | (10.83%) | (5.90%) | (2.42%) | (7.94%) | 17.35% | 17.51% | 10.64% | |
ROIC |
(13.10%) | (8.80%) | (6.80%) | (13.25%) | (9.94%) | 7.01% | (0.52%) | 35.95% | 36.86% | 31.75% |
Return on Tangible Assets |
(24.71%) | (19.68%) | (14.61%) | (21.07%) | (10.84%) | (5.17%) | (18.50%) | 29.84% | 31.17% | 15.03% |
Average Days of Receivables |
93.54 | 94.38 | 97.47 | 80.14 | 96.68 | 97.39 | 94.54 | 72.96 | 90.11 | 82.61 |
Research and Development Expense of Revenue |
51.92% | 45.71% | 38.88% | 43.80% | 37.99% | 24.79% | 24.53% | 16.28% | 15.75% | 21.95% |
Selling, General and Administrative Expense of Revenue |
50.17% | 46.67% | 48.11% | 51.19% | 51.87% | 46.83% | 53.13% | 41.47% | 41.42% | 47.53% |
Intangible Assets out of Total Assets |
0.24 | 0.19 | 0.16 | 0.13 | 0.10 | 0.08 | 0.06 | 0.04 | 0.04 | 0.03 |
Share Based Compensation of Revenue |
12.66% | 9.29% | 9.63% | 8.62% | 8.68% | 7.47% | 8.48% | 6.07% | 6.20% | 6.69% |
Graham Net Nets |
0.03 | 0.03 | 0.07 | 0.08 | 0.07 | 0.04 | 0.05 | 0.12 | 0.17 | 0.27 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.71 | 21.08 | 19.11 |
Earnings Yield |
(2.44%) | (1.87%) | (3.02%) | (6.18%) | (3.51%) | (1.29%) | (3.71%) | 7.51% | 7.75% | 5.25% |
Free Cash Flow Yield |
(1.26%) | (0.38%) | 0.66% | (0.56%) | 1.30% | 1.98% | (0.41%) | 7.43% | 8.54% | 10.45% |
Revenue per Share |
4.92 | 5.89 | 7.05 | 7.46 | 6.54 | 7.29 | 6.79 | 10.01 | 9.42 | 8.96 |
Operating CF per Share |
(0.42) | 0.13 | 0.64 | 0.46 | 0.52 | 0.63 | 0.13 | 2.41 | 2.66 | 3.16 |
Capex per Share |
(0.29) | (0.33) | (0.44) | (0.57) | (0.26) | (0.18) | (0.23) | (0.29) | (0.20) | (0.24) |
Free Cash Flow per Share |
(0.71) | (0.21) | 0.20 | (0.11) | 0.26 | 0.45 | (0.11) | 2.13 | 2.46 | 2.92 |
Cash per Share |
3.28 | 2.83 | 3.48 | 3.41 | 4.00 | 3.33 | 3.72 | 4.65 | 4.54 | 8.01 |
Shareholders Equity per Share |
7.98 | 7.84 | 7.55 | 6.91 | 6.72 | 6.91 | 6.37 | 7.24 | 8.86 | 11.05 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
7.98 | 7.84 | 7.55 | 6.91 | 6.72 | 6.91 | 6.37 | 7.24 | 8.86 | 11.05 |
Free Cash Flow |
(107.26) | (31.95) | 30.36 | (17.96) | 41.27 | 72.98 | (17.21) | 353.66 | 406.10 | 481.42 |
Working Capital |
578.69 | 517.72 | 643.48 | 570.86 | 672.71 | 590.88 | 632.56 | 965.29 | 950.16 | 1,385.72 |
Capital Expenditures |
(43.46) | (51.14) | (68.92) | (90.04) | (41.58) | (28.73) | (38.25) | (47.69) | (33.02) | (39.33) |
Net Current Asset Value |
273.74 | 214.43 | 329.53 | 242.01 | 228.22 | 150.27 | 210.08 | 551.97 | 824.77 | 1,261.46 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35.84 | 0.00 | 10.32 | 10.21 | 14.09 |
Capex to Sales |
0.06 | 0.06 | 0.06 | 0.08 | 0.04 | 0.02 | 0.03 | 0.03 | 0.02 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 38.30 | 0.00 | 11.49 | 11.31 | 18.15 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.36 | 0.35 | 0.33 | 0.22 | 0.23 | 0.23 | 0.35 | 0.33 | 0.13 | 0.12 |
Cash ROIC |
(5.39%) | (1.67%) | 1.53% | (0.95%) | 2.09% | 3.75% | (0.88%) | 15.60% | 18.32% | 15.34% |
Accounts Receivable Turnover |
4.30 | 4.25 | 4.16 | 4.26 | 3.90 | 3.99 | 3.70 | 5.36 | 4.34 | 4.11 |
Accounts Payable Turnover |
0.70 | 0.63 | 0.57 | 0.51 | 0.45 | 0.64 | 1.02 | 1.10 | 1.15 | 0.83 |
Inventory Turnover |
2.61 | 1.98 | 1.92 | 1.88 | 1.57 | 1.43 | 1.31 | 1.38 | 1.33 | 1.04 |
Average Days of Payables |
572.01 | 674.97 | 690.53 | 754.82 | 843.68 | 385.66 | 368.38 | 347.00 | 275.73 | 537.99 |
Days of Inventory on Hand |
174.04 | 220.01 | 186.61 | 205.99 | 257.38 | 278.08 | 303.66 | 268.89 | 272.10 | 365.31 |
Average Receivables |
173.29 | 212.35 | 262.91 | 274.65 | 266.11 | 294.17 | 300.58 | 310.22 | 358.50 | 359.28 |
Average Payables |
187.90 | 246.61 | 309.96 | 353.40 | 392.60 | 310.33 | 214.29 | 230.33 | 212.95 | 237.45 |
Average Inventory |
50.70 | 78.14 | 91.74 | 96.00 | 113.77 | 138.04 | 165.88 | 183.91 | 184.65 | 189.76 |
Average Assets |
1,791.08 | 1,761.83 | 1,811.12 | 1,815.21 | 1,877.57 | 1,987.11 | 1,994.23 | 2,050.10 | 2,095.90 | 2,271.28 |
Average Common Equity |
1,261.88 | 1,206.14 | 1,187.05 | 1,128.36 | 1,076.21 | 1,089.78 | 1,078.17 | 1,123.22 | 1,333.83 | 1,642.14 |
Columns are period end dates